source
- Ultragenyx prices Sanfilippo gene therapy at $4 million as it gains a second FDA approval; Bristol Myers halts Orum cancer drugThe FDA approved Fayuvi, the first gene therapy for Sanfilippo syndrome Type A, with a list price of $3.95 million. This marks Ultragenyx's second gene‑therapy approval since August, earning sella…
- U.S. drafts new investment rules to keep pharma licensing deals with China viableThe United States is drafting new guidelines that would govern how American investors can fund Chinese biotech and pharmaceutical companies. The proposed framework is intended to address national‑s…